Abstract
At the end of the 1990s, with the advent of imatinib for chronic myeloid leukemia and rituximab for B cell lymphoproliferative diseases with CD20 expression, there was a great conceptual evolution in the treatment of onco-hematological diseases. Researchers from around the world and the pharmaceutical industry began to focus their efforts on the so-called target therapy used alone or associated with classic chemotherapeutic drugs. In chronic lymphocytic leukemia, the development of second-generation anti-CD20 antibodies, biosimilars, PI3K (phosphatidylinositol 3-kinases) inhibitors, BTK (Bruton's tyrosine kinase) inhibitors, and anti-bcl 2 drugs represented mainly by venetoclax brought new, broader, and more effective opportunities in the treatment of this disease. This breakthrough occurred mainly regarding patients with alteration in 17p or mutation of the p53 gene for whom selecting the new drugs that act on B cell signaling (BTK and PI3K inhibitors) in the first line is mandatory. In fit patients with immunoglobulin heavy chain mutation, it is still acceptable to use the chemotherapy regimen with fludarabine, cyclophosphamide, and rituximab (FCR) and, in those who do not fit or are not IgVH-mutated, bendamustine-rituximab r...Continue Reading
References
Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
Oct 4, 2006·Oncogene·D ChauhanK C Anderson
Nov 14, 2006·Cancer Cell·Marina KonoplevaMichael Andreeff
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Jan 21, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sean D SullivanWen-Yi Shau
Apr 17, 2015·British Journal of Haematology·Gail L JonesUNKNOWN British Committee for Standards in Haematology
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Mar 10, 2016·Journal of Clinical Pharmacology·Suresh K AgarwalAhmed Hamed Salem
May 18, 2016·The Lancet Oncology·UNKNOWN International CLL-IPI working group
Nov 20, 2016·British Journal of Clinical Pharmacology·Suresh K AgarwalShekman L Wong
Jan 17, 2017·The Lancet Oncology·John F SeymourAndrew W Roberts
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew S DavidsJohn F Gerecitano
May 12, 2017·Future Oncology·Jennifer Crombie, Matthew S Davids
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
May 2, 2018·Blood Reviews·Benjamin W TehMonica A Slavin
May 2, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerWilliam G Wierda
May 12, 2018·Journal of Hematology & Oncology·Guilherme Fleury PeriniNelson Hamerschlak
Jun 14, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew S DavidsJohn F Seymour
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Apr 27, 2019·Blood·Andrew W RobertsJohn F Seymour
Jun 6, 2019·The New England Journal of Medicine·Kirsten FischerMichael Hallek
Jul 12, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenTalha Munir
Oct 20, 2019·Leukemia·Jan A BurgerThomas J Kipps
Nov 15, 2019·Blood·Constantine S TamWilliam G Wierda
May 10, 2020·PharmacoEconomics·Sang Kyu ChoScott Johnson
Jul 30, 2020·The New England Journal of Medicine·Jan A Burger
Sep 6, 2020·The Lancet Oncology·Othman Al-SawafKirsten Fischer
Sep 29, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnon P KaterJohn F Seymour
Dec 5, 2020·Hematology·Carol Moreno